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Abstract 
Background: The emergence and spread of multidrug-resistant Plasmodium falciparum and Plasmodium vivax high-
lights the need for objective measures of ex vivo drug susceptibility. Flow cytometry (FC) has potential to provide a 
robust and rapid quantification of ex vivo parasite growth.
Methods: Field isolates from Papua, Indonesia, underwent ex vivo drug susceptibility testing against chloroquine, 
amodiaquine, piperaquine, mefloquine, and artesunate. A single nucleic acid stain (i.e., hydroethidine (HE) for P. falci-
parum and SYBR Green I (SG) for P. vivax) was used to quantify infected red blood cells by FC-based signal detection. 
Data derived by FC were compared to standard quantification by light microscopy (LM). A subset of isolates was used 
to compare single and double staining techniques.
Results: In total, 57 P. falciparum and 23 P. vivax field isolates were collected for ex vivo drug susceptibility testing. 
Reliable paired data between LM and FC was obtained for 88 % (295/334) of these assays. The median difference of 
derived IC50 values varied from −5.4 to 6.1 nM, associated with 0.83–1.23 fold change in IC50 values between LM and 
FC. In 15 assays (5.1 %), the derived difference of IC50 estimates was beyond the 95 % limits of agreement; in eleven 
assays (3.7 %), this was attributable to low parasite growth (final schizont count < 40 %), and in four assays (1.4 %) due 
to low initial parasitaemia at the start of assay (<2000 µl−1). In a subset of seven samples, LM, single and double stain-
ing FC techniques generated similar IC50 values.
Conclusions: A single staining FC-based assay using a portable cytometer provides a simple, fast and versatile plat-
form for field surveillance of ex vivo drug susceptibility in clinical P. falciparum and P. vivax isolates.
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Background
Drug resistance remains a major obstacle to malaria 
control and emphasizes the importance of maintaining 
surveillance of anti-malarial efficacy to ensure optimal 
patient management and timely revision of treatment 
guidelines. Clinical trials are logistically difficult to con-
duct and their interpretation is confounded by host, 
parasite and drug factors. In vitro drug susceptibility 
testing provides an useful tool for monitoring drug resist-
ant malaria of the individual components of combination 
therapies and investigating potential novel anti-malarial 
compounds prior to clinical use [1].
Several drug susceptibility assays have been developed 
for anti-malarial compounds with parasite growth quan-
tified by enzyme-linked immunosorbent assay (ELISA) 
[2–4], fluorometry [5], or flow cytometry (FC) [6–8]. 
These assays have been applied to Plasmodium falcipa-
rum laboratory and field isolates, but have been limited 
for Plasmodium vivax drug susceptibility testing which 
remains still mostly reliant on microscopic quantification 
of parasite maturation [9–13]. The inability to sustain P. 
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vivax in in vitro culture results in drug testing having to 
be conducted on fresh isolates directly from patients with 
malaria; this is often undertaken in laboratories with lim-
ited resources. Quantification of parasite growth by light 
microscopy (LM) is relatively simple, inexpensive, and 
suitable for use in field settings. LM can also discriminate 
between different parasite stages, a feature that remains 
critical in quantifying short-term schizont maturation 
assays [10]. The marked stage-specificity of drug activity, 
particularly apparent for piperaquine in P. falciparum and 
for chloroquine in P. vivax assays, requires diligent atten-
tion to ensure a high proportion of early ring stages at the 
start of the assay [14]. However, LM has several significant 
shortcomings. The method requires skilled microscopists 
applying sustained concentration on a time-consuming 
task. Even when assays are performed by skilled micros-
copists, both inter-operator as well as intra-operator 
variation in parasite counts is observed, highlighting the 
subjective nature of the method [11]. LM is also unsuit-
able for medium to high throughput screening for novel 
drug candidates. Among the available drug susceptibil-
ity methods, FC-based approaches have the advantage of 
being able to identify different parasite stages and to deal 
with the low signal-to-noise ratio inherent with the low 
parasitaemia of clinical field isolates. Other colourimetric 
or fluorometric methods that depend on red blood cell 
lysis are vulnerable to auto-fluorescence which exacer-
bates the background noise [15, 16].
FC-based methods using a variety of staining and 
detection techniques have been developed and estab-
lished for drug susceptibility testing in P. falciparum lab-
oratory strains [17–19]. Although a simple, reagent-free 
assay based on the quantification of haemozoin, detected 
by the use of depolarizing side-scatter light filters has 
been reported [20, 21], most of the published assays are 
based on the detection of double-stranded DNA of Plas-
modium-infected erythrocytes since, with the exception 
of reticulocytes which generally account for ≤1 % of the 
red blood cell mass, uninfected erythrocytes do not con-
tain a nucleus [22]. Various nucleic acid dyes have been 
successfully applied to quantify parasite biomass, includ-
ing Hoechst [8], SYBR Green I [18], Thiazole Orange 
[17], SYTO-16 [23], and hydroethidine [24]. To date, few 
studies have described FC-based approaches for meas-
uring drug susceptibility in P. falciparum [25, 26] and P. 
vivax [27, 28] field isolates. The high capital and main-
tenance costs of the required hardware, the sensibility of 
its lasers, and the need for specifically trained personnel 
have also limited the applicability of the FC technology 
to field lab-based assays. However, the development of 
portable and affordable FC systems provides an excellent 
opportunity for facilitating and improving drug suscepti-
bility testing in Plasmodium field isolates.
The application of FC-based methods to P. vivax iso-
lates was first reported by Malleret et al. [29]. Russell and 
colleagues further modified this double staining method, 
demonstrating the feasibility of FC-based quantification 
of chloroquine and artesunate susceptibility in P. falcipa-
rum and P. vivax field isolates [27]. More recently, a simi-
lar approach using a combination of Hoechst 33342 and 
hydroethidine and a portable flow cytometer equipped 
with a near-UV laser has been described [28]. These 
studies showed good correlation between the LM- and 
FC-based methods. The aim of the current study was to 
rationalize the FC methods further by using a single stain 
technique that provides a simpler, more rapid and robust 
assay for higher throughput drug testing in the field.
Methods
Study site and subjects
The study was conducted at a field laboratory in Timika, 
Papua Province, Indonesia, a region where multidrug-
resistant P. falciparum and CQ-resistant P. vivax are highly 
prevalent [10, 30, 31]. Plasmodium species isolates were 
collected between 2012 and 2015, from patients with 
malaria attending an outpatient clinic. Patients with symp-
tomatic malaria were recruited into the study if they had 
a microscopically confirmed peripheral parasitaemia with 
monospecies of either P. falciparum or P. vivax between 
2000 and 80,000 µL−1. Patients were excluded from the 
study when they were younger than 2 years of age, had a 
haemoglobin level below 7  g/dL, or had anti-malarial or 
antibiotic treatment during the previous month. After 
obtaining written informed consent, blood was col-
lected by venepuncture. Host white blood cells (WBC) 
were removed by cellulose column filtration as previously 
described [32] and packed infected red blood cells (IRBC) 
were used for the ex vivo drug susceptibility assay.
Ex vivo drug susceptibility assay
Plasmodium drug susceptibility was measured using 
a protocol modified from the World Health Organiza-
tion (WHO) microtest as described previously [12, 13]. 
In brief, two hundred microlitres of a 2  % haematocrit 
blood medium mixture (BMM), consisting of RPMI 1640 
medium plus 10  % matched human serum (P. falcipa-
rum) or McCoy’s 5A medium plus 20 % matched human 
serum (P. vivax), was added to each well of pre-dosed 
drug plates containing 11 serial concentrations (two-fold 
dilutions) of the anti-malarials (maximum concentration 
shown in parentheses) CQ (2992 nM), piperaquine (PIP, 
1029  nM), mefloquine (MFQ, 338  nM), amodiaquine 
(AQ, 158 nM), and artesunate (AS, 49 nM). A candle jar 
was used to mature the parasites at 37  °C for 35–56  h. 
Incubation was stopped when >40 % of ring stage para-
sites had reached the mature schizont stage (i.e.,  ≥5 
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distinct nuclei per parasite) in the drug-free control well 
as determined by light microscopy (LM).
Anti‑malarial compounds
The anti-malarial drugs CQ, PIP, MFQ, AQ, and AS were 
obtained from the Worldwide Anti malarial Research 
Network (WWARN) QA/QC Reference Material Pro-
gramme [33]. The drugs were prepared as 1 mg/mL stock 
solutions in distilled water (CQ, PIP, MFQ, and AQ) or 
70 % ethanol (AS). Drug plates were pre-dosed by dilut-
ing the compounds in 50 % methanol, followed by lyophi-
lization, and stored at 4 °C. All drugs tested were assayed 
in duplicates. Drug plates were quality controlled by 
measuring drug response profiles in the CQ-resistant and 
CQ-sensitive laboratory strains K1 and FC27, respec-
tively, using the same method.
Plasmodium falciparum culture strains
Laboratory strains K1 and FC27 were obtained from 
MR4 (BEI Resources, ATCC Manassas, Virginia, USA). 
The parasites were kept in continuous in vitro culture as 
described previously [34]. To obtain highly synchronous 
parasite cultures, sorbitol treatment was applied once 
every week as described elsewhere [35].
Quantification of parasites by light microscopy
Thick blood films made from each well were stained with 
5  % Giemsa solution for 30  min and examined micro-
scopically. The number of mature schizonts per 200 
asexual stage parasites was determined for each drug 
concentration and normalized to that of the control well.
Quantification of parasites by flow cytometry
Staining of IRBCs for FC
The vital dye hydroethidine (HE, Sigma-Aldrich; exci-
tationmax/emissionmax =  535/610  nm) was used to stain 
IRBCs for P. falciparum infections and the nucleic acid 
dye SYBR Green I (SG, Invitrogen-Molecular Probes; 
excitationmax/emissionmax  =  497/520  nm) for P. vivax 
infections. HE was prepared as 10 mg/mL stock solution 
in dimethyl sulphoxide (DMSO) and stored at −20  °C. 
SG stock solution (10,000 × concentrate in DMSO) was 
stored as per the instruction manual at −20  °C. The 
working solution for HE was made by diluting the HE 
stock solution 1:250 in phosphate buffered saline (PBS, 
pH 7.4). The 1× working solution for SG was made by 
diluting the SG stock solution 1:10,000 in Tris-saline 
buffer (TSB, pH 8.5). Staining was performed by adding 
50 µL HE or 50 µL SG working solution to pelleted IRBCs 
(i.e., centrifugation at 1500  rpm, for 2  min) from 50  µL 
of the 2 % haematocrit BMM (final HE and SG concen-
tration: 0.63 mM and 1:2, respectively) for 25 min in the 
dark at 37  °C. After the incubation, IRBCs were washed 
(i.e., centrifugation at 1500  rpm, for 2  min) once with 
200  μL PBS, followed by final re-suspension in 200 µL 
PBS.
To further validate the single stain method, compari-
son was made with the double staining method published 
previously [27] using a subset of isolates obtained within 
the whole study. For the double staining method, 20 µL 
of BMM from each well at harvest were transferred to an 
empty 96-well plate and stained with a mixture of 2  μL 
HE 10 mg/mL solution, 30 μL of SG 1× working solution, 
and 48 μL PBS (final HE and SG concentration: 0.63  mM 
and 1:3.3, respectively). The mixture was incubated for 
20  min in the dark at room temperature. The reaction 
was stopped by adding 200 μL PBS to all wells.
Gating and quantification of parasites by FC
Samples were analysed using a dual-laser (blue: 488 nm, 
50 mW solid state; red: 640 nm, 30 mW diode) 3/1 emis-
sion detection configuration BD Accuri C6™ cytometer 
system equipped with a high-throughput 96-well sam-
pler (BD Accuri CSampler™). The blue laser was used for 
the detection of both dyes (SG in FL1: 530 ± 15 nm; HE 
in FL2: 585 ± 20 nm). The gating strategy is depicted in 
Fig.  1. First, cells were gated according to their FSC-H/
SSC-H profile to exclude debris from the red blood 
cell (RBC) population. Gating was then applied on the 
FSC-A/FSC-H profile to differentiate cell doublets from 
single cells. The gated single cell population was analysed 
further in either the SSC-H/FL2-H (P. falciparum) or the 
SSC-H/FL1-H (P. vivax) dot plot profiles. The mature 
schizont gate was set based on the drug-free control well 
and applied to all drug-treated wells. Gating procedure 
for HE and SG double staining was applied as described 
by Russell et al. [27]. For data acquisition, 100,000 events 
were analysed. In the case of low parasitaemia (i.e., less 
than 0.2 %), the number of events analysed was increased 
to 200,000. Automated analysis was performed using the 
BD Accuri CFlow Sampler™ software.
Statistical analysis
Dose–response data were analysed using nonlinear 
regression analysis (WinNonLn 4.1; Pharsight Corpo-
ration) and the 50  % inhibitory concentration (IC50) 
derived using an inhibitory sigmoid maximum effect 
(Emax) model. IC50 ex vivo data were only accepted if the 
Emax and E0 of the predicted curve were within 15  % of 
100 and 0, respectively. IC50 data with a high coefficient 
of variation (>100 %) and/or a high sum of squared resid-
uals (>1) were also rejected.
Agreement between quantification methods was 
assessed by Bland–Altman analysis using log-transformed 
IC50 data obtained with both methods [36]. Wilcoxon 
signed-rank test or Student’s t-test on log-transformed 
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data was used to assess the difference between paired 
samples using the different methods. All statistical analy-
ses were carried out using Stata (version 13.1, College Sta-
tion, Texas) and GraphPad Prism software (version 6.0).
Ethics
Ethical approval for this project was obtained from the 
Human Research Ethics Committee of the Northern Ter-
ritory Department of Health and Families and Menzies 
School of Health Research (HREC 2010-1396), Darwin, 
Australia, and the Eijkman Institute Research Ethics 
Commission (EIREC-47), Jakarta, Indonesia.
Results
Between May 2012 and February 2015, 57 P. falciparum 
and 23 P. vivax isolates were collected and successfully 
harvested for the comparative analysis of flow cytometry 
(FC) and light microscopy (LM) based quantification. 
Baseline characteristics of the isolates are presented in 
Table 1.
Of the 334 drug assays attempted, reliable data could be 
derived from 329 (98.5 %) of those assessed by LM and 
298 (89.2 %) by FC. The only difference in the proportion 
of successful assays arose for AS, for which LM produced 
reliable data in 96.5  % of P. falciparum isolates (55/57) 
and 100 % P. vivax isolates (23/23), compared to 66.7 % 
(38/57) and 73.9  % (17/23) assays by FC, respectively 
(Table  2). The low success rate for the artesunate assay 
was associated with the first batch of plates used in which 
44.1 % (15/34) failed assays for both P. falciparum and P. 
vivax, whereas this failure rate fell to 15 % (7/44) in the 
second batch of plates tested (p =  0.004). For all of the 
Fig. 1 Gating strategy for mature schizonts. Red blood cells (RBCs) were identified and gated based on the forward/side scatter (FSC-H/SSC-H) dot 
plot in gate ‘RBCs’. The RBCs were visualized in a FSC-A/FSC-H dot plot to select cell singlets in gate ‘Single RBCs’. The single RBCs were then analysed 
in a SSC-H/Hydroethidine-H (FL2-H) dot plot for P. falciparum and a SSC-H/SYBR Green 1-H (FL1-H) dot plot for P. vivax. Mature schizonts were identi-
fied in gate ‘MS’ based on fluorescence intensity and side scatter values (i.e., increased DNA content and cell complexity) produced by schizonts 
compared to other Plasmodium life cycle stages
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other drugs tested, reliable data could not be obtained for 
a total of 10 assays and this was attributable to technical 
errors; for nine assays, the number of acquired events by 
FC was too low and for one assay, microscopy slide prep-
aration was inaccurate.
In total, 294 (88 %) assays could be quantified by both 
LM and FC. The median IC50 values for all isolates with 
successful LM and FC assays are depicted in Fig. 2. These 
ex vivo drug susceptibility data are in concordance with 
ex vivo IC50 estimates produced in parallel studies in the 
area confirming a high level of CQ resistance in both 
Plasmodium species in Papua Indonesia [37, 38].
There were significant, albeit modest differences in 
IC50 values derived by LM and FC for PIP [median dif-
ference  =  6.1  nM (range −18.7 to 21.0  nM)] and AQ 
[median difference =  2.8 nM (range −2.7 to 15.1 nM)], 
in P. falciparum isolates. No significant differences were 
observed between methodologies for P. vivax (Table 3).
Bland–Altman plots are presented in Fig.  3 for each 
drug according to the species tested and the differences 
in IC50s in Table  3. From the 285 P. falciparum assays, 
there were 11 (3.86 %) outliers with differences in derived 
IC50s up to 60 nM for CQ, 18 nM for PIP, 19 nM for MFQ, 
15 nM for AQ, and 3.6 nM for AS. In P. vivax, there were 
four (3.5 %) outliers out of 115 assays with maximum val-
ues of 60  nM for CQ, 27.5  nM for PIP, 40  nM for AQ, 
and 5  nM for AS. Eleven (73  %) of these outliers were 
identified to be attributable to isolates with a low initial 
parasitaemia at the start of the assays (<2000 parasites/
µL), and four isolates due to low schizont counts (<40 %) 
at harvest associated with arrested trophozoite develop-
ment or gametocytogenesis, ultimately resulting in sub-
optimal harvest. 
To compare single with double staining, a subset 
of seven isolates (5 P. falciparum and 2 P. vivax) were 
assessed by both the single staining method presented in 
the current study and the double staining method pub-
lished by Russell et al. [27]. The results are summarized in 
Table 4. Overall, similar IC50 values were obtained when 
these methods were compared in both P. falciparum 
laboratory strains and clinical P. falciparum and P. vivax 
field isolates.
Discussion
Methods for quantifying ex vivo growth of Plasmodium 
that include parasite staging are currently limited to light 
microscopy (LM) and flow cytometry (FC). The present 
study provides a head-to-head comparison of these two 
approaches highlighting the utility and advantages of a 
single staining FC method. The assay was easy to apply in 
a remote field laboratory and produced results compara-
ble to the LM-based method. Successful paired assay data 
Table 1 Baseline characteristics of isolates for which ex vivo assays were accomplished
CI confidence interval
a No range given (all values were 100 %)
b Percentage of mature schizonts per asexual blood stage parasites determined by light microscopy
Baseline characteristics P. falciparum
n = 73
P. vivax
n = 28
Total number of isolates reaching harvest (%) 57 (78 %) 23 (82 %)
Median (range) delay from venepuncture to start of culture (minutes) 130 (80–225) 175 (90–330)
Median (range) duration of assay (hours) 44 (32–55) 46 (30–50)
Geometric mean (95 % CI) parasitaemia (asexual parasites/µL) 18,867 (14,423–24,680) 35,509 (20,433–61,707)
Median initial percentage (range) of parasites at ring stage 100a 96 (77–100)
Mean (95 % CI) schizont count at harvestb 45 (41–49) 40 (35–46)
Table 2 Percentage of successful assays with reliable data
a Number of drug assays attempted
Anti‑malarial P. falciparum P. vivax
na Light microscopy Flow cytometry na Light microscopy Flow cytometry
Chloroquine 57 56 (98.2 %) 55 (96.5 %) 23 23 (100 %) 21 (91.3 %)
Mefloquine 39 39 (100 %) 39 (100 %) 17 17 (100 %) 14 (82.3 %)
Piperaquine 57 56 (98.2 %) 55 (96.5 %) 23 23 (100 %) 21 (91.3 %)
Amodiaquine 25 24 (96.0 %) 25 (100 %) 13 13 (100 %) 13 (100 %)
Artesunate 57 55 (96.5 %) 38 (66.7 %) 23 23 (100 %) 17 (73.9 %)
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could be generated in 88 % of drug assays, although the 
success rate was somewhat lower for AS when using FC 
(66.7 and 73.9  % for P. falciparum and P. vivax, respec-
tively), compared to LM (96.5 and 100  % for P. falcipa-
rum and P. vivax, respectively). The failure to quantify 
artesunate susceptibility appeared to be related to a spe-
cific batch of drug plates that was, by mistake, stored at 
ambient temperature which resulted in 44.1  % (15/34) 
failed assays compared to a subsequent batch in which 
the number of failed assay decreased to 15 % (7/44).
During the initial phase of assay development using 
P. falciparum laboratory strains, cell staining was per-
formed using HE. However, early experiments with 
P. vivax field isolates did not yield consistent results, 
with some isolates failing to produce sufficient fluores-
cent signals to distinguish both uninfected RBCs versus 
infected RBCs (IRBC) and the different life cycle stages; 
the results confounded the gating procedure for P. vivax 
isolates. Alternative nucleic acid (NA) dyes were tested 
(SYBR Safe nucleic acid stain, Thiazole Orange, SYTO 16, 
and SYBR Green I). SYBR Green I (SG) was chosen for 
P. vivax since it resulted in significantly better resolution 
of the different RBC and IRBC populations with clear 
separation between schizonts and other life cycle stages. 
However, the HE stain produced the optimal results for 
P. falciparum isolates, with good resolution of different 
RBC and IRBC populations and higher signal-to-noise 
ratio compared to SG. A comparative analysis of the sin-
gle staining method with the HE plus SG double stain-
ing method previously published by Russell et al. [27] was 
conducted in two P. falciparum laboratory strains and a 
subset of five P. falciparum and two P. vivax clinical field 
isolates summarized in Table 4. Both methods produced 
comparable results and appear suitable for assessing anti-
malarial drug susceptibility (Table  2). The advantage of 
using HE or SG single staining is that there is no need to 
run single stain controls in each experiment in order to 
compensate for spectral overlap that occurs when double 
staining methods using fluorescent dyes with close exci-
tation/emission spectra such as HE and SG are applied. 
Therefore, the presented single staining method greatly 
facilitates raw FC data analysis.
Overall, the drug susceptibility data quantified by LM 
and FC were similar. Statistically significant differences 
in IC50 values were observed for PIP and AQ in P. fal-
ciparum. However, the median differences were modest 
(6.1 nM for PIP and 2.8 nM for AQ), all within the con-
fidence bounds of the assay and therefore, unlikely to be 
of biological or clinical significance. In total, there were 
15 outliers with higher differences in IC50s derived by FC 
and LM. Several factors are likely to have contributed to 
these outliers, the most notable of which was a reduced 
parasite count, either from a low starting parasitaemia 
(lower than 2000 parasites/µL), or inadequate parasite 
growth leading to a low final mature schizont count 
below 40  %. Quantification of low parasite densities is 
a recognized factor undermining the confidence of LM 
or FC [10, 14]. Given the time-consuming and subjective 
nature of LM-based assays, those assays with reduced 
parasite count increase the workload on the microsco-
pists, which leads to lower assay reading accuracy. The 
reliability of FC data can be improved by increasing the 
number of acquired events that enables greater confi-
dence in gating the schizont population. Another poten-
tial confounding factor in the comparison of the LM and 
FC data is the presence of abnormal (unhealthy) schiz-
onts, which occur following drug treatment and/or sub-
optimal growth. The LM-based method requires visual 
quantification of mature schizonts with  >5 chromatin 
dots, whereas abnormal schizonts with irregular chro-
matin dots plus altered shape and size are not classified 
as mature schizonts. However, these abnormal schizonts 
cannot be readily distinguished with the FC method 
since quantification is based on side scatter properties 
Fig. 2 Ex vivo drug susceptibility of P. falciparum (upper pannel) 
and P. vivax (lower panel) clinical isolates by light microscopy (closed 
circles) or flow cytometry (open circles). Numbers represent median 
IC50s (nM) for each drug tested
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Fig. 3 Bland-Altman plots of LM and FC derived IC50s. IC50 values of each drug tested in P. falciparum (left) and P. vivax (right). Dotted lines represent 
the 95 % limits of agreement between LM and FC
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and nucleic acid content, irrespective of the parasites’ 
fitness.
The FC-based quantification approach offers fast, 
field applicable, objective and transparent post assay 
sample processing and data acquisition. LM-based 
quantification requires assay harvest, thick blood film 
preparation from each drug well, slide drying, Giemsa 
staining, followed by slide reading and cross checking 
of microscopy. For a standard assay of one Plasmodium 
isolate, testing four drugs on a 96-well format, this can 
be accomplished between 16 and 20  h. The FC-based 
approach requires cell staining, washing, and final re-
suspension and data acquisition by FC, with a total aver-
age processing time of 2 h. The assay procedure per se 
(i.e., sample preparation and assay duration of 52–56 h) 
and data analysis (i.e. pharmacodynamics modelling of 
raw drug response data) does not differ between the two 
approaches. Hence, between 14 and 18 man hours can 
be saved, varying according to the LM and FC skills of 
the operators.
The FC approach also has the advantage of requiring 
a smaller volume of blood than LM quantification. In a 
typical run, less than 0.2 µL packed RBCs from the 2 % 
haematocrit BMM is required for each assay. A reduction 
in the blood volume required for each drug assay should 
increase the number of drugs that can be tested in paral-
lel from the same volume of blood. The savings in pro-
cessing costs and human resources counter balance the 
higher initial costs for hardware and maintenance for FC 
and make this a viable field adapted technology.
Conclusion
The single staining FC-based quantification of ex  vivo 
parasite growth provides a rapid and reliable estimate of 
Table 3 Difference in IC50 estimates (nM) derived by light microscopy (LM) and flow cytometry (FC)
CI confidence interval
a p-values obtained from paired t- test on log-transformed IC50 derived by LM and FC
Anti‑malarial P. falciparum P. vivax
n Mean [95 % CI] 
difference in IC50 
LM‑FC (nM)
Median [Range] 
difference in IC50 
LM‑FC (nM)
Δ IC50 LM‑FC
p valuea
n Mean [95 % CI] 
difference in IC50 
LM‑FC (nM)
Median [Range] 
difference in IC50 
LM‑FC (nM)
Δ IC50 LM‑FC
p valuea
Chloroquine 54 −3.8 [−10.7 to 3.2] −5.1 [−60.9–59.4] 0.124 21 −4.5 [−16.0 to 7.1] −5.4 [−46.1–60.2] 0.725
Piperaquine 54 6.0 [3.8 to 8.2] 6.1 [−18.7–21.3] <0.001 21 0.7 [−4.6 to 6.0] −4.5 [−15.2–27.5] 0.425
Mefloquine 39 1.3 [−0.6 to 3.1] 0.1 [−5.7–18.6] 0.969 14 1.2 [−3.6 to 6.0] 2.8 [−13.9–15.8] 0.931
Amodiaquine 24 4.0 [1.9 to 6.0] 2.8 [−2.7–15.1] 0.002 13 4.7 [−4.3 to 13.7] 0.4 [−11.8–40.2] 0.864
Artesunate 38 −0.4 [−0.7 to −0.01] −0.25 [−3.6–2.9] 0.077 17 −0.12 [−0.9 to 0.7] −0.45 [−2.2–5.0] 0.102
Table 4 IC50 values derived by different staining methods in P. falciparum laboratory strains and clinical Plasmodium iso-
lates
CQ chloroquine, PIP piperaquine, MFQ mefloquine, AS artesunate
a Mean IC50s (derived from 2 independent experiments)
b Assay quantification by flow cytometry (FC) using single staining with hydroethidine (HE) for P. falciparum
c Assay quantification by FC using double staining with HE and SG for both species [27, 29]
d LM light microscopy
e Assay quantification by flow cytometry (FC) using single staining with SYBR Green I (SG) for P. vivax
Anti‑malar‑
ial
Mean IC50 (nM) in P. falciparum laboratory lines
a Clinical Plasmodium isolates
FC27 (CQ sensitive) K1 (CQ resistant) P. falciparum (n = 5)
Median IC50 (nM, range)
P. vivax (n = 2)
IC50 estimates (nM)
Singleb Doublec LMd Singleb Doublec LMd Singleb Doublec LM Singlee Doublec LMd
CQ 25.1 23.7 20.7 171.0 167.0 159.4 85.0 
(52.8–165.0)
97.3 
(52.9–179.0)
108 
(65.6–115.0)
92.2; 132.0 88.5; 150.0 102.0; 113.0
PIP 32.8 32.5 34.7 63.0 63.9 89.7 35.0 
(19.9–45.0)
38.6 
(12.6–57.1)
47.5 
(27.6–68.4)
79.1; 153.0 85.6; 155.0 91.8; 115.0
MFQ 46.8 40.9 49.9 16.6 14.5 9.4 10.2 
(3.5–19.3)
10.2 
(2.2–23.3)
9.4 
(3.6–15.5)
23.0; 43.0 30.3; 42.4 17.7; 22.6
AS 4.1 4.3 2.6 8.7 7.8 6.0 2.2 (1.3–3.1) 2.2 (1.9–3.7) 1.9 (1.2–2.6) 2.6; 6.3 2.8; 6.7 3.1; 7.8
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drug response. Its implementation in field laboratories to 
replace or complement the time-consuming and labour-
intensive LM-based method has potential to greatly facil-
itate surveillance and screening of anti-malarial agents.
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